Memantine

Generic Name: Memantine

Brand Names: Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₁N

CAS Number: 19982-08-2

Unique Ingredient Identifier: W8O17SJF3T

Background: Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...

Indication: Memantine is used to manage moderate to severe Alzheimer's dementia .
...

Associated Conditions: Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases

Phase 1

Conditions: Alzheimer Disease
Battery

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2014-11-11

Last Posted Date: 2019-06-27

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 30

Registration Number: NCT02288000

Locations: 🇫🇷
CHRU de Lille/ Centre d'investigation Clinique, Lille, France
🇫🇷
CIC Marseille, Marseille, France
🇫🇷
CIC Toulouse, Toulouse, France

An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder

Phase 4

Completed

Conditions: PTSD

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2014-10-08

Last Posted Date: 2020-05-22

Lead Sponsor: Sriram Ramaswamy

Target Recruit Count: 26

Registration Number: NCT02258828

Locations: 🇺🇸
Omaha Veterans Affairs Medical Center, Omaha, Nebraska, United States

Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury

Not Applicable

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2014-09-15

Last Posted Date: 2017-08-30

Lead Sponsor: Indiana University

Target Recruit Count: 11

Registration Number: NCT02240589

Locations: 🇺🇸
Indiana University Health Facilities, Indianapolis, Indiana, United States

Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects

Not Applicable

Conditions: Schizophrenia

Interventions: Drug: Memantine

First Posted Date: 2014-09-08

Last Posted Date: 2015-12-14

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 20

Registration Number: NCT02233556

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Impact of Persistent Conductances on Motor Unit Firing in SCI

Not Applicable

Conditions: Chronic Spinal Cord Injury

Interventions: Drug: Memantine
Procedure: Therapeutic muscle stretching
Drug: sugar pill
Drug: Riluzole
Drug: Isradipine

First Posted Date: 2014-05-13

Last Posted Date: 2014-05-13

Lead Sponsor: Shirley Ryan AbilityLab

Target Recruit Count: 50

Registration Number: NCT02136823

Therapy in Amyotrophic Lateral Sclerosis (TAME)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis
Frontal Temporal Dementia

Interventions: Drug: Memantine
Drug: Placebo (for Memantine)

First Posted Date: 2014-04-21

Last Posted Date: 2022-11-29

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 89

Registration Number: NCT02118727

Locations: 🇺🇸
UC Irvine, Irvine, California, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
CoxHealth, Springfield, Missouri, United States

and more 10 locations

A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers;
Obese, Otherwise Healthy Volunteers

Interventions: Drug: Baclofen
Drug: Memantine
Drug: Placebo

First Posted Date: 2013-12-05

Last Posted Date: 2014-07-08

Lead Sponsor: Gedeon Richter Plc.

Registration Number: NCT02001584

Locations: 🇬🇧
Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom

Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia

Phase 3

Conditions: Schizophrenia

Interventions: Drug: Memantine
Drug: Placebo

First Posted Date: 2013-12-04

Last Posted Date: 2016-07-12

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 120

Registration Number: NCT02001103

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Open-label Study of Safety and Tolerability of Memantine in Children With Autism

Phase 2

Completed

Conditions: Autism
Pediatric Autism

Interventions: Drug: Memantine HCl

First Posted Date: 2013-12-03

Last Posted Date: 2014-03-18

Lead Sponsor: Forest Laboratories

Target Recruit Count: 102

Registration Number: NCT01999894

Locations: 🇺🇸
Forest Investigative Site 024, Jacksonville Beach, Florida, United States
🇺🇸
Forest Investigative Site 013, Cleveland, Ohio, United States
🇺🇸
Forest Investigative Site 006, Voorhees, New Jersey, United States

and more 16 locations

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

Phase 3

Completed

Conditions: Autism Spectrum Disorder

Interventions: Other: Placebo
Drug: Memantine

First Posted Date: 2013-10-30

Last Posted Date: 2024-07-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 84

Registration Number: NCT01972074

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy